ReviewCNS neuroscience & therapeutics2026
Mesenchymal Stem Cell-Based Therapy for Cerebellar Ataxia: From Bench to Bedside.
Review in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionCerebellar ataxia (CA) encompasses hereditary and acquired disorders unified by Purkinje cell loss and neuroinflammation, for which no disease-modifying therapy exists. Human mesenchymal stem cells (hMSCs) offer multimodal neuroprotection through paracrine secretion of neurotrophic factors and immunomodulatory mediators.
methodsWe reviewed preclinical and clinical evidence for hMSC therapy across multiple CA etiologies, integrating findings from neuroinflammatory, toxic/developmental, and genetic mouse models alongside published clinical trials and case reports. A systematic literature search was conducted in PubMed/MEDLINE, Embase, and the Cochrane Library (search period: 2000-2026) using the following key terms: "mesenchymal stem cell" AND "cerebellar ataxia"; "MSC" AND "spinocerebellar ataxia"; "hMSC" AND "Purkinje cell"; "stem cell therapy" AND "ataxia". Inclusion criteria encompassed: peer-reviewed original research articles and reviews in English; in vivo animal model studies; clinical trials, case series, and case reports. Studies addressing non-CA neurological conditions without CA-relevant data were excluded.
resultshMSC transplantation consistently improved motor function, preserved Purkinje cell integrity, and attenuated neuroinflammation across LPS-induced, Ara-C-induced, and SCA2 transgenic models. A critical observation is that MSCs from CA patients exhibit markedly reduced anti-inflammatory secretome capacity compared with healthy-donor MSCs, justifying an allogeneic strategy. Therapeutic efficacy was maintained even after symptom onset in the SCA2 model. A published case report demonstrated safety and preliminary functional benefit of intrathecal allogeneic bone marrow-derived MSCs in a sporadic adult-onset ataxia patient.
conclusionshMSC therapy targets convergent CA pathomechanisms-microglial suppression, neurotrophin restoration, and Purkinje cell preservation-through a paracrine rather than cell-replacement mechanism. Post-symptomatic efficacy and an emerging clinical evidence base support advancing toward placebo-controlled randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.